Navigation Links
NIH-funded trial launched to assess experimental TB drug
Date:12/11/2012

A clinical trial will examine an investigational drug's early bacteria-killing activity in patients newly diagnosed with drug-sensitive pulmonary tuberculosis. The clinical trialsponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Healthis being led by researchers at the Tuberculosis Research Unit at Case Western Reserve University in Cleveland. The study to take place in Cape Town, South Africa, will enroll 75 men and women with TB ages 18 to 65, including individuals who are also infected with HIV but not yet taking antiretroviral treatment.

In 2011, 8.7 million people worldwide became infected with TB, and 1.4 million people died, according to the World Health Organization. Co-infection with TB causes one quarter of all deaths among those infected with HIV. South Africa has the highest TB infection rate in the world and accounts for 5 percent of the global TB burden. The country also has the highest TB/HIV co-infection rate, 73 percent.

"New, simplified treatments that cure TB infection more quickly are desperately needed," said NIAID Director Anthony S. Fauci, M.D. "It has been nearly 50 years since a new drug specifically developed for TB was licensed. This is a relatively small study, but we hope it yields insights into whether this investigational drug shows promise in people who are newly diagnosed with TB, as laboratory and earlier clinical safety trials indicate it might."

The clinical trial will assess the investigational TB drug developed by AstraZeneca, based in London. In laboratory testing, the drug proved active against a wide range of drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis (Mtb), the bacterium that causes TB disease. In two preliminary human studies in the United States, testing multiple doses, the oral drug was generally well-tolerated. Some study participants experienced gastrointestinal and blood-related adverse events at higher doses, but these effects were reversible and not serious.

To be eligible to participate in the new trial, patients must have newly diagnosed pulmonary TB as confirmed through a positive sample of mucus and saliva (sputum). HIV-infected patients who are not currently taking antiretrovirals and who have a CD4+ T-cell count of greater than 350 cells per cubic millimeter are eligible for the study. CD4+ T-cells are a key marker of immune system health.

Study volunteers will be randomly assigned to one of five study groups, each with 15 participants. In four groups, all participants will receive a 14-day regimen of the experimental drug, but at different dosages and frequencies: 500 milligrams (mg) once daily; 500 mg twice daily; 800 mg twice daily; and 1200 mg twice daily.

The study lasts only 14 days because of the potential risk of drug resistance emerging in TB patients receiving a single drug for a prolonged period of time.

Participants in the fifth study group will receive the standard TB treatment of 14 days of rifafoura four-drug combination pill containing isoniazid, rifampin, ethambutol and pyrazinamidedosed according to the study participants' body weight. After the 14-day study, all participants will receive standard TB drugs to treat their disease.

Researchers will examine daily sputum samples from the study participants to determine whether the investigational drug is reducing their TB bacteria counts, and if so, to what extent. Information about clinical trial NCT01516203 is available at http://www.clinicaltrials.gov. For more information about TB research, visit the NIAID Tuberculosis webpage.


'/>"/>

Contact: Sara Crocoll
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. NIH-funded study finds high HIV infection rates among gay and bisexual black men in the US
2. NIH-funded analysis estimates effective PrEP dosing
3. Brain Tumor Vaccine Shows Promise in Early Trial
4. URMC clinical trial tests new regimen for hypertension
5. Analysis Finds Clinical Trials Often Small, of Poor Quality
6. US spends far more for health care than 12 industrialized nations, but quality varies
7. New Weight-Loss Drug Shows Promise in Trial
8. Palpitations are predictive of future atrial fibrillation
9. Trial Set to See if Drug Can Prevent Alzheimers
10. Experts call for clinical trials to test non-skeletal benefits of vitamin D
11. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology: